Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology. Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas […]
Diabetes
Glytec enters insulin management partnership with Nebraska Medicine
Glytec announced today that it entered into a strategic partnership with Nebraska Medicine to advance patient safety and innovation in insulin management. Under the agreement, Nebraska Medicine will implement Glytec’s eGlycemic Management System (eGMS) across all 800 beds at its two hospitals: the Nebraska Medical Center and Bellevue Medical Center. The agreement also includes collaboration […]
MIT team working on all-in-one diabetes management devices
MIT researchers are touting a platform aimed at helping patients maintain healthy glucose levels by streamlining the diabetes management process. The MIT researchers say it’s hard for people with diabetes to maintain a treatment regimen. Typically at every meal, they need to estimate carbohydrate content, draw blood to measure blood glucose levels, and calculate the […]
Fractyl Health touts preliminary data from diabetes reversal study
Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 […]
FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set
Capillary Biomedical announced today that it received FDA investigational device exemption (IDE) for its SteadiFlow infusion technology. Irvine, California-based Capillary Biomedical designed its new SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability. The SteadiSet infusion set, powered by the SteadiFlow technology platform, features an integrated […]
Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a significant regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As […]
Roche launches its connected blood glucose meter in Europe
Roche announced today that it launched its Cobas Pulse system in select countries accepting CE mark approval in Europe. Basel, Switzerland–based Roche designed its Cobas Pulse system to combine the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities comparable to that of a smartphone. The platform joins Roche’s […]
Glytec partners with Roche to enhance insulin dosing decision support software
Glytec announced today that it entered into a strategic partnership with Roche Diagnostics USA for a digital health collaboration. Waltham, Massachusetts-based Glytec’s partnership combines its FDA-cleared Glucommander insulin dosing decision support software with Roche’s expertise in medical devices and IT solutions in an effort to address the challenges associated with inpatient blood sugar management at […]
California aims to produce inexpensive insulin
California Governor Gavin Newsom has signaled that the state would pursue manufacturing insulin to offer the hormone at a reduced cost to people with diabetes. “Insulin should not drain your bank account,” Newsom shared over Twitter. Newsom has also made contract manufactured insulin part of the proposed budget planning for the fiscal year 2022. Get […]
Dexcom CEO touts unprecedented performance of G7 in clinical trial, awaits FDA decision
Exciting new data for the next-generation Dexcom (NSDQ:DXCM) G7 continuous glucose monitor (CGM) surprised even the company’s leadership. Dexcom Chair, President & CEO Kevin Sayer, presenting clinical study results for the G7 at the 40th Annual J.P. Morgan Healthcare Conference, has previously lauded the expected impact of the wearable glucose monitor, and the new data […]